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Summary 2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine
which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug
remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50
human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise
the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared
its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were
conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate
that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens
reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator
nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside.
The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of
multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class.
The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may
help to elucidate drug activities and mechanisms of action.
2-Chlorodeoxyadenosine is an adenosine deaminase resistant
analogue of deoxyadenosine (Carson et al., 1980) which has
shown clinical activity in human hematologic neoplasms in
Phase I and Phase II clinical trials (Carson et al., 1984; Piro
et al., 1988; Piro et al., 1990; Santana et al., 1991). Very
recently two additional clinical trials have been published
confirming activity of 2-CDA in acute leukaemias (Santana
et al., 1992) and low grade lymphomas (Kay et al., 1992).
The mode of action of this drug remains the subject of
investigation, however its ability to kill resting as well as
proliferating lymphocytes (Seto et al., 1985; Carson et al.,
1983), toxicity to peripheral blood monocytes (Carrera et al.,
1989; Carrera et al., 1990) and relative non-cross resistance
with other nucleoside analogues in cell lines (Seto et al.,
1985; Carrera et al., 1990) has intensified interest in the drugs
clinical potential. To characterise the activity spectrum of
2-CDA, we utilised the Differential Staining Cytotoxicity
(DiSC) assay in 50 fresh human tumour specimens obtained
from patients with a variety of hematologic malignancies.
The DiSC assay, originally described by Weisenthal et al.
(1983) has previously been shown to correlate with both
response and survival in solid and hematologic neoplasms
(Tidefelt et al., 1989; Lathan et al., 1990; Bosanquet, 1991;
Gazdar et al., 1990). Our intent was to assess the disease-
specific activity of this agent in vitro and to compare its
relative cytotoxicity with that of other antineoplastic agents
in current clinical use. Comparisons were conducted against
nitrogen mustard, doxorubicin, vincristine and cytosine
arabinoside.
Materials and methods
Drugs
2-Chlorodeoxyadenosine (kindly provided by Dr Charles
Carrera and Dr Dennis Carson of the Scripps Clinic and
Research Institute) was prepared in a 0.15 M NaCl solution
at a stock concentration of 1 mM, then aliquoted into
cryovials and stored at - 70C for later use. Doxorubicin
(Adriamycin; Adria Laboratories, Columbus, Oh.), nitrogen
mustard (Mustargen; Merck, Sharp and Dohme, West Point,
Pa.), vincristine sulfate (LymphoMed, Melrose Park, Il.) and
ARA-C (cytarabine; Upjohn, Kalamazoo, Mi.) were ob-
tained from the Memorial Medical Center pharmacy. Stock
concentrations were prepared in 0.15 M NaCl solution, ali-
quoted and stored at - 70°C. Drug stability was assessed
spectrophotometrically and drug cytotoxicity was confirmed
by activity against transformed human lymphocytes and cell
lines. Drug stability has been the subject of a prior report
(Bosanquet, 1985).
Samplepreparation
Fresh human tumour specimens were placed in Roswell Park
Memorial Institute-1640 media (Irvine Scientific, Irvine, Ca.)
containing 15% heat-inactivated foetal bovine serum or 40%
heat-inactivated horse serum (Irvine Scientific, Irvine, Ca.)
penicillin (100 IU ml'), streptomycin (100 jig ml'), 2 mM
glutamine, and 15 units ml-' preservative-free heparin for
transport to the laboratory. Tumour cells from peripheral
blood and bone marrow specimens were isolated by centri-
fugation over Lymphocyte Separation Medium (Organon tek-
nicka, Durham, N.C.). Cells at the interface were aspirated
by Pasteur pipet and washed twice in RPMI 1640 media.
Lymphatic tissues containing Non-Hodgkin's Lymphoma
were dissociated by mincing in a media-containing petri dish
with scissors and forceps. Cells were collected with a Pasteur
pipet and resuspended in media. The number of viable cells
in each specimen was determined using 0.4% trypan blue in
0.15 M NaCI in a standard hemocytometer counting
chamber. Specimen selection for 2-CDA investigation was
based upon the adequacy of the sample to provide sufficient
tissue for study. The overall success rate for DiSC assays
during the time of this investigation ranged from approx-
imately 75% to over 90%.
Assayprocedure
The DiSC assay, as previously described (Bird et al., 1986) is
a 4-day cell culture with continuous drug exposure in conical
polypropylene microtubes. Cytotoxic drugs were thawed and
serial dilutions were prepared; 201il of each drug solution at
the concentration to be tested was added to 80 1l of the cell
suspension. Control tubes contained vehicle (0.15 M NaCI)
alone. All control and drug treated tubes were incubated for
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4 days at 37°C in an atmosphere containing 5% CO2. Fol-
lowing the incubation, 100 jil nigrosin/fast green dye contain-
ing 37,500 acetaldehyde-fixed red blood cells (DRBCs) was
added to each culture tube, which was briefly vortexed. After
10min, samples were cytocentrifuged onto glass slides, air-
dried and stained with a Wright/Giemsa stain. Cell survival
was determined as the ratio of living tumour cells over
simultaneously counted DRBCs for each slide using a Whip-
ple disc, with cell survival of drug-treated samples being
expressed as a percentage of the saline control values. Our
experience has shown that multiple myeloma specimens
maintain higher viability in RPMI 1640 enriched with 40%
(v/v) horse serum. For the purpose of this study both 15%-
FCS and 40%-horse-sera containing media were used in
different myeloma samples.
Statistical anallsis
Statistical analyses were performed using BMDP Statistical
Software (BMDP Statistical Software, 1440 Sepulveda Blvd.,
LA, CA. 90025). Analysis of variance (ANOVA) was used to
determine overall differences between samples grouped by
disease. The non-parametric (Kruskall-Wallace) test was also
applied for comparison with the ANOVA results. The Dun-
can Multiple Range Test (confidence level set at 95%) and
Tukey Studentized Range Method were used to further iden-
tify differences between specific disease groups. Correlation
coefficients were used to compare the activity of 2-CDA with
other classes of chemotherapeutics.
Results
A comparison of the mean and median IC50 values and
ranges for 2-CDA in each of the disease types tested is
provided in Figure 1. All IC50s were calculated from 5 or 10
point dose response curves, using the median effect method
of Chou and Talaly (1987). The relatively similar IC50 values
for ALL, AML, CLL, HCL and NHL (median range
11.98-22.65 nM; mean range 19.90-86.87 nM) are in sharp
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contrast to the IC50 of multiple myeloma (median 863.64 nM;
mean 1750.11 nM). An analysis of variance (ANOVA) for
2-CDA IC50 found a significant different between groups
(diseases), F(4,41) = 4.64 (P<0.01). Further analysis using a
Duncan Multiple Range Test (95% confidence level)
identified multiple myeloma as significantly different from all
other disease groups. The Tukey Studentized Range Method
indicated that multiple myeloma was significantly different
from NHL and CLL (P<0.01); and from ALL and AML
(P<0.05). An ANOVA for the IC70 of 2-CDA also found a
significant difference (P<0.001) between groups, F(4,41)=
8.96. Applying the Duncan Multiple Range Test (95%
confidence level), multiple myeloma was again identified as
being significantly different from all other disease groups. To
confirm the ANOVA findings we also applied a non-
parametric test (Kruskal-Wallis) which indicated that the IC50
value for Multiple myeloma was significantly different from
all other groups (P = 0.0026).
Pearson sample correlation coefficients (r-values) were cal-
culated for each two drug comparison i.e. ARA C v's 2-CDA,
doxorubicin vs 2-CDA, nitrogen mustard vs 2-CDA, and
vincristine vs 2-CDA and are provided in Figure 2.
Significance levels for each comparison were determined by
Two-Tailed T. When all tumour types are included, the
correlation coefficient for nitrogen mustard Ivs 2-CDA is 0.82,
for an N of 33 (P<0.001) while all other drugs do not
indicate significant correlation with 2-CDA. A comparison of
the r-values for the highly 2-CDA resistant multiple myeloma
samples and relatively 2-CDA sensitive CLL samples is pro-
vided at the bottom of Figure 2. Despite wide variation in
the 2-CDA IC50s for these two disease types, the correlation
with nitrogen mustard persists.
To assess the impact of protein binding upon 2-CDA
activity in multiple myeloma specimens, we correlated the in
vitro serum concentrations with the 2-CDA IC50 values for
eight multiple myeloma specimens. Samples were studied in
15% (v/v) Fetal Calf Serum or 40% (v/v) Horse Serum.
Wilcoxon rank sum results indicated a P value = 0.39, which
does not support a relationship between serum concentration
and IC50 for 2-CDA.
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Figure 1 Comparison of 2-CDA IC5o values in human hematologic neoplasms: Mean and median IC,o values are provided for
each tumour type: Acute Lymphoblastic Leukaemia (ALL); Acute Myelogenous Leukaemia (AML); Non Hodgkin's Lymphoma
(NHL); Hairy Cell Leukaemia (HCL); Chronic Lymphocytic Leukaemia (CLL); Multiple Myeloma (MYE). Sample IC50 Ranges
(nM): ALL = 0.12 115.8; AML = 1.34-50.0; CLL = 0.01 -250; NHL = 0.01 422; HCL = 17.2 50.0; MYE = 50.0 8,004.12 R.A. NAGOURNEY et al.
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Figure 2 Correlation coefficients of each 2-drug comparison: Tumour specimens in which multiple drugs were studied in parallel
provide cytotoxicity result correlations. Cytarabine (ARA-C); Doxorubicin (DOX); Nitrogen Mustard (NM); Vincristine (VCR).
Lower portion of Figure 2 shows correlations between 2-CDA and NM in Chronic Lymphocytic Leukaemia (CLL) and Multiple
Myeloma (MYE).
Discussion
Preliminary observations in vitro with 2-CDA conducted
between 1984 and 1985 at the Scripps Clinic and Research
Foundation and reported in abstract (Nagourney et al., 1989)
indicated significant cytotoxicity in a variety of human
hematologic neoplasms. This was consistent with the clinical
activity originally described in Phase I by Carson et al. (1984)
and confirmed in Phase II trials (Piro et al., 1988; Piro et al.,
1990; Santana et al., 1991; Santana et al., 1992; Kay et al.,
1992). Despite 2-CDA's activity in several lymphatic neo-
plasms, initial in vitro studies revealed little or no activity in
the B cell neoplasm multiple myeloma (Nagourney et al.,
1989). The current report describes observations from 50
specimens of human hematologic tumours and confirms the
lack of in vitro activity for 2-CDA in multiple myeloma. The
relatively similar IC50 ranges for both myeloid and most
lymphoid neoplasms are in sharp contrast to the mean IC50
of multiple myeloma specimens which is two orders of
magnitude greater (P<0.01). Although non specific protein
binding was considered, experiments conducted in which the
in vitro serum concentrations ranged from 15% FCS (v/v) to
40% Horse serum (v/v) revealed no measurable impact upon
cytotoxicity.
The in vitro activity of 2-CDA in both myeloid and lym-
phoid neoplasms indicated by relatively similar IC50 ranges
suggests potentially broad clinical activity. Avery et al. (1989)
described significant activity for 2-CDA in cell lines derived
from T, B, and non-T/non-B lineages. The significant degree
of variance between cell lines was similar to the inter-
specimen variability evident in our primary cultures studies.
2-CDA has demonstrated clinical activity in Chronic Lym-
phocytic Leukemia (Piro et al., 1988) Hairy Cell Leukemia
(Piro et al., 1990), Acute Leukemia (Santana et al., 1991;
Santana et al., 1992) and low grade lymphomas (Kay et al.,
1992). The current report is consistent with these observa-
tions. The significant difference observed in vitro between
multiple myeloma and other tumour types however, strongly
suggests that the clinical activity spectrum does not extend to
this neoplasm. We recently reported that the multiple
myeloma is significantly more resistant in vitro to ARA C
than other hematologic neoplasms as well (Nagourney et al.,
1991). Both 2-CDA and ARA C are substrates for 2-
deoxycytidine kinase which could theoretically underlie the
observed correlation in this disease. Inadequate sample size
of myeloma specimens tested in parallel against both ARA C
and 2-CDA in the current study precluded calculation of a
myeloma-specific correlation for these two drugs.
We compared the in vitro activity of 2-CDA with that of
ARA C, vincristine, nitrogen mustard and doxorubicin to
assess cross resistance patterns. Pemble et al. (1987) reported
non-cross resistance between ARA C and 2-bromodeoxy-
adenosine (2-BDA) in human myeloid leukaemia. Similarly,
we found no correlation between 2-CDA and ARA C nor
between 2-CDA and vincristine or doxorubicin. However,
correlation was observed between 2-CDA and the alkylating
agent nitrogen mustard. Subset analysis performed upon the
relatively 2-CDA-sensitive CLL specimens and highly 2-
CDA-resistant multiple myeloma specimens indicated that
cross resistance was present in both data sets despite their
widely different IC5s'S for 2-CDA. Avery (1989) identified
synergy between 2-BDA and AZQ in cell lines in vitro. Of
interest, AZQ is believed to act by alkylation (Akhatar et al.,
1975). In preliminary experiments, we have now identified
true synergy, by isobologram and computer analysis (Chou &
Talalay, 1987), between 2-CDA and the alkylator nitrogen
mustard in 4/4 specimens of CLL. Of interest, this degree of
synergy was not observed between 2-CDA and gamma
irradiation in which only 1/4 CLL specimens revealed
synergy and only at suprapharmacologic concentrations.
These observations suggest a relationship between the modes
of action or mechanisms of resistance of 2-CDA and the
mustard alkylators which may not extend fully to gamma
irradiation, i.e. depurination.
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Conceptually, a laboratory assay which assesses the
activity of a chemotherapy drug by measuring total cell kill
in a largely non-dividing population of cells should be valid
and correlate with clinical outcome if (i) the mechanisms of
cell kill in vitro are related and proportional to the
mechanisms of cell kill in vivo or (ii) the mechanisms of
cellular resistance in vitro are related and proportional to the
mechanisms of resistance in vivo.
Prior investigations have shown that 2-CDA causes
significant cell kill in non dividing populations (Seto et al.,
1985; Carson et al., 1983). Seto et al. reported that exposure
to 2-CDA results in activation of poly ADP ribose
polymerase with resultant depletion of cellular NAD and
subsequent cell death (Seto et al., 1985). Activation of Poly
ADP ribose polymerase has been identified following radia-
tion and alkylator exposure (Berger et al., 1979; Smulson et
al., 1977; Berger, 1985). 2-CDA has also been shown to
inhibit DNA polymerases, induce depurination and to result
in double-strand DNA breaks (Hentosh et al., 1990; Griffig
et al., 1989; Tanabe et al., 1989). These activities are all
associated with the actions of alkylators. The chemical struc-
ture of 2-CDA does not suggest a free-radical mechanism as
its mode of action nor as a basis for cross resistance with
alkylators. However, activation of Poly ADP ribose poly-
merase, inhibition of DNA polymerases, single or double
strand breaks, depurination or as-yet-unrecognised actions
could underlie the observed cross resistance pattern. If
confirmed, these results suggest novel therapeutic strategies
utilising combinations of alkylators and 2-CDA as promising
directions for future clinical trials.
In conclusion, this report confirms our original observa-
tions utilising the DiSC assay (Nagourney et al., 1989) regar-
ding the in vitro activity spectrum of 2-CDA in primary
cultures of human neoplasms. The current report describes in
vitro activity for this agent in a variety of human
hematologic neoplasms with the distinct exception of mul-
tiple myeloma. Within given tumour types inter-specimen
variation was also observed. Finally, we have observed
significant cross resistance between 2-CDA and nitrogen
mustard and preliminary evidence of synergy between these
agents. The DiSC assay has previously been shown to cor-
relate with both response and survival in a variety of human
neoplasms. In this regard, it may serve as a conduit for newly
derived agents to enter clinical testing predicated upon the
activity spectra identified in vitro. Since the time of our
original in vitro studies with 2-CDA, several clinical trials
have established the activity for this drug in many of the
neoplasms that we had examined and reported upon in ab-
stract form. At the time of this writing we are unaware of
any published data regarding the clinical activity of 2-CDA
in multiple myeloma. We await the completion of further
clinical trials to allow a prospective assessment of the predic-
tive accuracy of these in vitro observations.
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